Skip Navigation

skip navigationNIDDK Home
NIDDK Reference Collection
Diet   Exercise   Health  
Home Page
-  

FAQ

Detailed Search

- -
NIDDK INFORMATION SERVICES
- -

Diabetes

Digestive Diseases

Endocrine and Metabolic Diseases

Hematologic Diseases

Kidney and Urologic Diseases

Weight-control Information Network

-
NIDDK EDUCATION
PROGRAMS

- -

National Diabetes Education Program

National Kidney Disease Education Program

-
- - -
NIDDK Home
-
Contact Us
-
New Search
-
Topic: hematologic diseases (he)
Title: Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion.
Author: Lazarus, H.M.; Luger, S.
Source: IN: Hematology 2007.Washington, DC: American Society of Hematology. 2007. pp 444-452.
Availability: Available from American Society of Hematology. 1900 M Street NW, Suite 200, Washington, DC 20036. Email: ASH@hematology.org. Website: www.asheducationbook.org. Price: Available free of charge on website.
Abstract: This chapter, from the Hematology 2007 monograph, considers the factors involved in the decision to proceed to hematopoietic stem cell transplant (HSCT) for adult patients with acute lymphoblastic leukemia (ALL). The authors note that relapse and nonrelapse mortality continue to plague the outcome of HSCT even when undertaken in complete remission (CR). Those considered to be at high risk for relapse often are considered for HSCT in first complete remission (CR1), whereas those at lower risk may not be referred until they have relapsed, when their chances for cure are very poor. In some patients who have a suitable histocompatible sibling, disease- or patient-related factors may override the potential benefit of allogeneic HSCT. Because many patients do not have a suitable histocompatible sibling, one has to consider the relative merits of autologous transplantation versus use of an alternative allogeneic stem cell source such as a matched-unrelated donor (MUD), umbilical cord blood (UCB) donor, or haploidentical donor. Deciding among these options versus chemotherapy—even in high-risk patients—is difficult. In the review, the authors discuss the risks and benefits of these choices to determine whether and by what means to proceed to HSCT in adult patients with ALL who are in CR1. The authors present two case studies of patients with ALL and a discussion of how the data provided would lead to a decision about the selection of therapy. 1 figure. 3 tables. 52 references.

Format: Monograph/Book
Language: English.
Major Keywords: Hematologic Diseases. Stem Cells. Transplantation. Patient Selection. Leukemia. Myelodysplastic Syndromes. Morbidity. Mortality.
Minor Keywords: Cancer Therapy. Patient Care Management. Case Reports. Risk Factors. Age Factors. Remission. Blood Donation. Histocompatibility. Chemotherapy.
Publication Number: HEBK10258
Printer-Friendly Version | Return to Search Results
<-- previous record | next record -->

View NIDDK Publications | NIDDK Health Information | Contact Us

The NIDDK Reference Collection is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
NIDDK Clearinghouses Publications Catalog
5 Information Way
Bethesda, MD 20892–3568
Phone: 1–800–860–8747
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: catalog@niddk.nih.gov

Privacy | Disclaimers | Accessibility | Public Use of Materials
H H S logo - link to U. S. Department of Health and Human Services NIH logo - link to the National Institute of Health NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases